Securities Times online newsCleopatrafreeslotsAzure Bio (603739) (603739) rose again by the daily limit on the 8th. As of press time, the stock was at 18.Cleopatrafreeslots.47 yuan, with nearly 230000 orders sealed on the trading board. So far, the stock has risen by the limit for six consecutive trading days.

The company issued a risk reminder last night that the company's stock price has been volatile recently, with a short-term increase significantly higher than that of the Shanghai Composite Index over the same period, there is overheated market sentiment and there may be irrational hype. After self-examination, the company's current production and business activities are normal. There are no major adjustments in the market environment or industry policies, no significant fluctuations in production costs and sales, and normal internal production and operation order.

Recently, the Internet and some media have released relevant reports on "synthetic Biology". The company's main business is the R & D, production and sales of enzyme preparations, microecological preparations and animal health products. According to the company's 2023 annual report, the income of enzyme preparation is 441 million yuan, accounting for 37.49% of the main business income; the income of microecological products is 237 million yuan, accounting for 20.14% of the main business income; the income of animal health products is 297 million yuan, accounting for 25.24% of the main business income; the income of other products is 202 million yuan, accounting for 17.12% of the main business income.

The company has set up only one synthetic biotechnology innovation laboratory in the field of synthetic biology, which is mainly used for the research and development of functional proteins for feed, food sweeteners and so on. However, the laboratory reserves of few R & D projects, small amount of investment, small allocation of professionals, is still in the early stage of strain laboratory research and development, there is still a large gap from large-scale scale-up, and does not have the conditions for industrialization. The production of synthetic biological products involves separation, purification and other production processes, and the purification process is difficult, the company does not have this process at present, and needs to be further developed. At the same time, the future of the product may also involve registration and regulatory approval, product selection and marketing, etc., with a long cycle, difficulty, and significant uncertainty in commercialization. It is expected that in a long time, it will not have a significant impact on the operation of the company. In addition, the company does not involve R & D investment in other areas of synthetic biology.